Search results
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 7 days agoThe company noted that it achieved 48% market share for Covid vaccines in the U.S. during the fall...
Gateway - The Root
The Root· 2 days agoThe Biden administration is expected to announce this week that Americans who got the Pfizer-BioNTech or Moderna vaccines will need the third shot to protect themselves against ...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 6 days ago"We are interested in seeing how effective Sanofi FP is at raising consumer awareness of Novavax's...
7 Struggling Stocks to Sell Before July 2024
InvestorPlace via Yahoo Finance· 7 days agoThe stock market’s surge continues, with several major market indices making new all-time highs recently. The explosion of artificial intelligence and...
Gateway - Quartz
Quartz· 14 hours agoLike many other wealthy nations, the country bought many more vaccines than it needed—a total of nearly 32 million—to account for potential quality issues, or supply delays. This week, the nation ...
Results are looking promising for a combined COVID and flu vaccine. Here’s how it could benefit...
The Conversation· 5 days agoEarlier this week, Moderna announced positive results for its phase 3 clinical trial of a combined vaccine against COVID and influenza. Combination vaccines have been successfully ...
GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the...
NewMediaWire via Yahoo Finance· 1 day ago10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen,...
COVID Variant KP.3 Surges to Dominance—Here's What You Need to Know
Health via Yahoo News· 6 days agoPer Zambrano, all three COVID vaccine manufacturers—Pfizer, Moderna, and Novavax—have said that...
Vaccine Effectiveness against SARS-CoV-2 among Household Contacts during Omicron BA.2–Dominant...
Centers for Disease Control and Prevention· 22 hours agoVaccine Effectiveness among Household Contacts
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 7 days agoThough it has a booster Covid shot, like rivals Moderna and Novavax, analysts don't expect sales to...